Section Arrow
Quote
AUPH.NASDAQ
- Aurinia Pharmaceuticals
Quotes are at least 15-min delayed:2024/04/29 02:16 EDT
Last
 4.91
+0.04 (+0.82%)
Day High 
5.01 
Prev. Close
4.87 
1-M High
5.41 
Volume 
985.50K 
Bid
4.9
Ask
4.95
Day Low
4.86 
Open
4.89 
1-M Low
4.71 
Market Cap 
704.29M 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 4.99 
20-SMA 5.04 
50-SMA 5.35 
52-W High 12.43 
52-W Low 4.71 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.54/0.87
Enterprise Value
786.30M
Balance Sheet
Book Value Per Share
2.61
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
175.51M
Operating Revenue Per Share
1.10
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8601+0.0824+10.60%-- 
BDRXBiodexa Pharmaceuticals plc1.3+0.5752+79.36%-- 
KTRAKintara Therapeutics0.1488-0.0092-5.82%-- 
JAGXJaguar Health0.18+0.01+5.88%-- 
IBRXImmunityBio7.35+2.24+43.84%-- 
Quotes are at least 15-min delayed：2024/04/29 02:16 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.